Ssri Snri Dosing Comparison
SSRI & SNRI Dosing Comparison for Anxiety Disorders
Quick Reference Tool | PsychHQ Source: Module 3, Pharmacotherapy (Lessons 1, 8, 12) | Last Updated: March 2026
Why SSRIs Are First-Line for Anxiety
Anxiety effect sizes for SSRIs are larger than for depression across meta-analyses. A 2025 Cochrane review (37 RCTs, 12,226 GAD patients) found an NNT of 7 (number needed to treat — patients who receive the drug for one to experience clinical response) for response, with an NNH of 17 (number needed to harm — patients treated for one to discontinue due to side effects). That risk-benefit ratio holds across anxiety diagnoses. Unlike depression, SSRIs show a clear linear dose-response for anxiety: higher doses produce additional benefit (NNT 14-16 for the incremental gain), which means dose optimization matters more here than in depression prescribing.
Bottom line: Full dose escalation in partial responders is warranted before declaring treatment failure. Anxiety-specific dose-response curves justify pushing to maximum tolerated doses.
Agent-by-Agent Comparison
| Feature | Sertraline | Escitalopram | Fluoxetine | Paroxetine | Fluvoxamine |
|---|---|---|---|---|---|
| Half-life | 26 hrs | 27-32 hrs | 2-4 days (parent); 7-15 days (norfluoxetine) | 21 hrs | 15-20 hrs |
| Selectivity | Moderate (weak sigma-1, DAT) | Highest SERT selectivity (30x R-enantiomer) | Moderate | Moderate (anticholinergic activity) | Moderate (sigma-1 agonist) |
| Key evidence | CAMS (Child Anxiety Multimodal Study) anchor; broadest anxiety evidence base | NMA tolerability leader | Depression data strongest; anxiety data adequate | Strong GAD/SAD data (odds ratio 3.02-3.14 vs placebo) | RUPP: 76% pediatric response vs 29% placebo |
| Monotherapy response | 55% (CAMS, ages 7-17) | High response, superior tolerability profile | Comparable to other SSRIs | Comparable to other SSRIs | 76% pediatric SAD/GAD (RUPP) |
| Combination (+ CBT) | 81% (CAMS) | Not tested in equivalent trial | Not tested in equivalent trial | Not tested in equivalent trial | Not tested in equivalent trial |
| CYP interactions (hepatic drug-metabolism enzymes) | Weak CYP2D6 inhibitor | Weakest CYP profile of all SSRIs | Strong CYP2D6 inhibitor (phenoconversion risk) | Strong CYP2D6 inhibitor | Strong CYP1A2, CYP2C19 inhibitor |
| Discontinuation risk | Low (IR 0.18) | Low-moderate | Very low (IR 0.15; self-tapers via long half-life) | Very high (35% symptoms vs 14% placebo; FINISH syndrome) | Moderate |
| Activation risk | Moderate | Low | Highest | Moderate | 45% activation cluster (RUPP pediatric) |
| Pediatric preferred? | Yes (CAMS-supported) | Yes (selectivity advantage) | Yes (long half-life buffers missed doses) | No (discontinuation profile) | Caution (high activation rate) |
| Best clinical niche | Default first choice; broadest evidence | Elderly, medically complex, polypharmacy | Adherence concerns (missed-dose tolerant) | Avoid first-line; OK if prior documented response | Pediatric SAD/GAD if others fail |
SNRI Positioning
SNRIs are not first-line for anxiety. Reserve for specific indications.
| Feature | Venlafaxine XR | Duloxetine |
|---|---|---|
| Half-life | 5 hrs (active metabolite ODV: 11 hrs) | 12 hrs |
| Mechanism at clinical doses | <150 mg = functionally SSRI; true dual action requires >150-225 mg | Balanced SERT + NET inhibition across all therapeutic doses |
| NNT (GAD remission) | ~8 | ~8 (47% normal functioning vs 28% placebo) |
| FDA anxiety indications | GAD, SAD, PD (adults) | GAD in adults AND children 7+ (only SSRI/SNRI with pediatric anxiety indication) |
| Dose-response for anxiety | No clear dose-response — higher doses don't improve efficacy but increase side effects | Moderate dose-response |
| Discontinuation risk | Very high (IR 0.40; most severe of all antidepressants) | Moderate |
| Unique side effect | Dose-dependent hypertension (monitor BP at every visit during titration, especially >150 mg) | Hepatic transaminase elevation (rare) |
| When to choose | Failed 2 SSRI trials + need mechanistic switch, or prominent somatic anxiety | Anxiety + chronic pain/fibromyalgia (dual indication) |
SNRI prescribing reality: Venlafaxine below 150 mg is pharmacologically an SSRI. If a patient "failed venlafaxine" at 75 mg, they haven't actually tried an SNRI — they've tried a suboptimal SSRI with a worse discontinuation profile.
Dosing: Adult vs. Pediatric
Adult Starting and Target Doses
| Agent | Starting Dose | Titration | Target Range | Maximum |
|---|---|---|---|---|
| Sertraline | 50 mg daily | Increase by 25-50 mg every 2-4 weeks | 100-200 mg/day | 200 mg/day |
| Escitalopram | 10 mg daily | Increase to 20 mg after 4 weeks if needed | 10-20 mg/day | 20 mg/day |
| Fluoxetine | 20 mg daily | Increase by 10-20 mg every 4 weeks | 20-60 mg/day | 80 mg/day |
| Paroxetine | 20 mg daily | Increase by 10 mg every 2-4 weeks | 20-50 mg/day | 60 mg/day |
| Fluvoxamine | 50 mg at bedtime | Increase by 50 mg every 4-7 days | 100-300 mg/day | 300 mg/day |
| Venlafaxine XR | 75 mg daily | Increase by 75 mg every 4 days (per label) | 150-225 mg/day | 225 mg/day |
| Duloxetine | 30 mg daily | Increase to 60 mg after 1-2 weeks | 60 mg/day | 120 mg/day |
Pediatric Starting and Target Doses
Anxiety patients are more sensitive to activation side effects than depressed patients — slower titration is standard.
| Agent | Pediatric Start | Titration | Pediatric Target | Notes |
|---|---|---|---|---|
| Sertraline | 12.5-25 mg | Increase by 12.5-25 mg every 1-2 weeks | 50-150 mg/day | CAMS-supported; ages 7-17 |
| Fluoxetine | 5-10 mg | Increase by 5-10 mg every 1-2 weeks | 10-40 mg/day | Long half-life = forgiving for missed doses; liquid formulation available |
| Escitalopram | 5 mg | Increase to 10 mg after 2-4 weeks | 10-20 mg/day | High selectivity = clean side-effect profile |
| Duloxetine | 30 mg (ages 7+) | Increase to 60 mg after 2 weeks | 30-60 mg/day | Only agent with FDA pediatric anxiety indication |
"Start low, go slow" is grounded in the RUPP fluvoxamine data: 45% of children experienced activation cluster events (hyperactivity, behavioral disinhibition, intense agitation) at standard dosing vs. 4% on placebo. Use liquid formulations when available for precise pediatric dosing. Younger children (7-11) need lower starting doses and slower titration than adolescents (12-17).
Selection Algorithm
Step 1: Start with an SSRI
- Default choice: Sertraline (broadest anxiety evidence, CAMS anchor, low discontinuation risk)
- If tolerability is the priority (elderly, medically complex, polypharmacy): Escitalopram (cleanest CYP profile, highest selectivity)
- If adherence is a concern (inconsistent dose-taking): Fluoxetine (long half-life buffers missed doses, self-tapers on discontinuation)
- Pediatric default: Sertraline or fluoxetine; escitalopram if CYP interaction concerns
Step 2: Optimize before switching
- Titrate to maximum tolerated dose (anxiety has a clear dose-response curve — unlike depression)
- Allow 8-12 weeks at therapeutic dose before declaring failure
- Reassess comorbidities: untreated depression, SUD, ADHD, thyroid dysfunction, or cardiac arrhythmias can sustain anxiety despite adequate SSRI
Step 3: If 2 SSRIs fail, consider SNRI
- Duloxetine if comorbid chronic pain or fibromyalgia
- Venlafaxine XR if somatic anxiety predominates — but ensure dosing reaches >150 mg for true dual mechanism
- SNRIs show no dose-response in anxiety; don't push beyond 225 mg venlafaxine expecting additional benefit
Step 4: Escalation beyond SSRI/SNRI → See Treatment-Resistant Anxiety Algorithm tool
Monitoring Essentials
All SSRI/SNRI patients:
- Standardized anxiety measure at every visit: GAD-7 (Generalized Anxiety Disorder 7-item scale), SCARED (Screen for Child Anxiety Related Disorders) for pediatric, or disorder-specific scales like the LSAS (Liebowitz Social Anxiety Scale) or PDSS (Panic Disorder Severity Scale)
- Actively ask about sexual dysfunction — 30-70% incidence, most common reason for unilateral discontinuation without telling you; paroxetine > others
- Ask about emotional blunting — 80% of patients with SSRI sexual dysfunction also report this (Opbroek et al., 2002); not depression — it's a drug effect on the mesolimbic reward pathway (the brain's pleasure and motivation circuit)
- Side effect assessment at each titration visit
Pediatric-specific monitoring:
- AAP/AACAP: weekly contact for first month (Black Box Warning requirement); practically, 2-4 week intervals acceptable for milder cases if clinical contact is established
- Watch for activation syndrome in first 1-2 weeks: increased anxiety, agitation, insomnia, irritability, hyperactivity, emotional lability
- Telehealth and nurse check-ins supplement face-to-face visits
SNRI-specific (venlafaxine):
- Blood pressure at every visit during titration and dose increases (hypertension is dose-dependent, emerges >150 mg/day)
Duration and Discontinuation
How long to treat:
- Continue minimum 12 months after achieving remission (guideline-standard across agencies)
- Relapse risk is substantially higher if discontinued at 3-6 months
- SAD and GAD may warrant even longer maintenance given high relapse rates
Tapering protocol:
- Standard: 25-50% dose reduction every 2-4 weeks to minimum available dose
- If standard taper fails: Hyperbolic tapering (progressively smaller dose reductions — e.g., from 50% cuts → 25% → 10% → 5% — to minimize withdrawal at each step) — 72% of patients who failed linear tapering succeeded with this approach (Horowitz & Taylor, 2019)
- Requires liquid formulations or compounding for sub-tablet doses in final stages
Distinguishing discontinuation from relapse:
- Discontinuation: onset within days of dose reduction; neurological symptoms not part of original disorder (dizziness, "brain zaps," paresthesias, visual disturbances); rapid resolution on reinstating medication
- Relapse: develops gradually over weeks; resembles original symptom pattern
Pregnancy and lactation:
- Sertraline and escitalopram have the largest safety databases; no consistent teratogenic risk
- Avoid paroxetine (FDA cardiac malformation warning, particularly VSD with first-trimester exposure)
- Neonatal adaptation syndrome in ~20-30% of third-trimester SSRI-exposed neonates (transient, typically mild, self-limiting)
- Untreated severe anxiety also carries risks (preterm birth, low birth weight, postpartum complications)
- Breastfeeding: sertraline most favorable (minimal infant serum levels)
Key References: Cochrane Systematic Review (2025, 37 RCTs, GAD); Walkup et al. (2008, CAMS, NEJM); RUPP Anxiety Study Group (2001, NEJM); Cortese et al. (2018, Lancet Psychiatry); 2024 Lancet Psychiatry discontinuation meta-analysis (79 studies); Horowitz & Taylor (2019, Lancet Psychiatry); Opbroek et al. (2002, J Clin Psychiatry)